Premium
Brotizolam, a triazolothienodiazepine, in insomnia
Author(s) -
Rickels Karl,
Morris Richard J,
Mauriello Richard,
Rosenfeld Howard,
Chung Hack R,
Newman Harris M,
George Case W
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.179
Subject(s) - placebo , insomnia , medicine , clinical pharmacology , anesthesia , double blind , adverse effect , hypnotic , pharmacology , alternative medicine , pathology
Sixty‐three outpatients with chronic insomnia were treated for 3 weeks under double‐blind conditions with either brotizolam (n = 29) at a dose of 0.25 mg or 0.5 mg or placebo (n = 34). A 3‐day placebo period preceded and followed the double‐blind treatment phase. Brotizolam consistently produced significantly more sleep improvement than placebo but also more adverse effects. In those patients switched abruptly from brotizolam to placebo, rebound insomnia was observed, being most marked at the first post‐brotizolam placebo night. Clinical Pharmacology and Therapeutics (1986) 40, 293–299; doi: 10.1038/clpt.1986.179